Biology

Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences

Friday, February 26, 2021 - 9:04pm

The replays will be available for at least 30 days following the presentation.

Key Points: 
  • The replays will be available for at least 30 days following the presentation.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
  • For more information please visit www.pacb.com and follow @PacBio .

FIU: When devastation strikes the oceans, sharks can hold the key to recovery

Friday, February 26, 2021 - 5:03pm

Predators, including some sharks, are known to be critical for maintaining stability and biodiversity in the world's oceans.

Key Points: 
  • Predators, including some sharks, are known to be critical for maintaining stability and biodiversity in the world's oceans.
  • But according to a new study, they are also critical in helping ecosystems recover when devastation hits from hurricanes or marine heatwaves.
  • In a unique study, a team of scientists tested whether an ecosystem could recover if sharks were no longer there to keep other animals in check.
  • Recovery from the heatwave has been slow but aided by the seasonal presence of sharks.

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

Friday, February 26, 2021 - 4:05pm

"We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse," saidRobb Knie, CEO of Hoth Therapeutics.

Key Points: 
  • "We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse," saidRobb Knie, CEO of Hoth Therapeutics.
  • "We believe that the HT-KIT pathway is a promising novel target for combating both mast cell-derived cancers and mast cell-mediated anaphylaxis.
  • Hoth also intends to pursue the anaphylaxis indication for HT-KIT in parallel to cancer treatment and HT-004 development.
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

Worldwide Preparative and Process Chromatography Industry to 2028 - Increasing Demand for Monoclonal Antibodies is Driving Growth

Friday, February 26, 2021 - 3:30pm

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Preparative and Process Chromatography Market Size, Share & Trends Analysis Report by Product (Process Chromatography, Preparative Chromatography), by Type, by End Use, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Preparative and Process Chromatography Market Size, Share & Trends Analysis Report by Product (Process Chromatography, Preparative Chromatography), by Type, by End Use, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global preparative and process chromatography market size is expected to reach USD 17.26 billion by 2028.
  • High demand for monoclonal antibodies, coupled with the growing adoption of preparative chromatographic techniques in the bioprocessing industry, is anticipated to boost the revenue growth in the market over the forecast period.
  • Extensive R&D activities in the Asian pharmaceutical market result in the growing demand for chromatography products.

Cord Blood Banking Leader Cryo-Cell International Enters Into An Exclusive License Agreement with Duke University

Friday, February 26, 2021 - 2:30pm

The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.

Key Points: 
  • The agreement grants Cryo-Cell the rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke.
  • These treatments utilize the unique immunomodulatory and potential regenerative properties derived from cord blood and cord tissue.
  • Under the agreement, Cryo-Cell has been granted exclusive commercial rights to Dukes intellectual property assets, FDA regulatory data, clinical expertise and manufacturing protocols associated with various applications of cord blood and cord tissue stem cells.
  • More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their babys cord blood and cord tissue stem cells.

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

Friday, February 26, 2021 - 1:00pm

HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021.

Key Points: 
  • HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021.
  • We are very excited to share what we believe is compelling data generated in studies performed since the demonstration of initial feasibility with the release of White Paper Two today.
  • In all three assessments, the panel demonstrated a high degree of accuracy when measuring differential gene expression and in comparison to RNA-Seq, continued Dr. Navratil.
  • The Companys proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

Friday, February 26, 2021 - 12:00pm

An audio webcast will be accessible through the Investor Relations section of the companys website https://ir.fulcrumtx.com/events-and-presentations .

Key Points: 
  • An audio webcast will be accessible through the Investor Relations section of the companys website https://ir.fulcrumtx.com/events-and-presentations .
  • Following the live webcast, an archived replay will also be available.
  • Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
  • Fulcrums proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

Asia Pacific Amniotic Membrane Market to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Friday, February 26, 2021 - 12:22pm

The "Asia Pacific Amniotic Membrane Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Enzyme; Application; End User, and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Amniotic Membrane Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Enzyme; Application; End User, and Country" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the Asia Pacific amniotic membrane market is mainly attributed to the factors such as rise in applications of amniotic membrane and growing geriatric population.
  • Based on enzyme, the Asia Pacific amniotic membrane market is segmented into cryopreserved amniotic membrane and dehydrated amniotic membrane.
  • Helps to takeknowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific amniotic membrane market.

Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies

Friday, February 26, 2021 - 12:00pm

Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing.

Key Points: 
  • Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing.
  • Artiva plans to use the proceeds from the financing to advance its NK cell therapy development programs and expand ongoing research and development activities.
  • Artivas cell therapies are designed to leverage the innate anti-tumor biology and safety features of NK cells.
  • Artivas manufacturing platform supports large-scale production and cryopreservation of off-the-shelf allogeneic NK cell therapies, and proprietary CAR-NK and NK-specific gene-editing technologies to augment therapeutic activity.

Global Cancer Molecular Diagnostics Markets 2021-2025 - New Diagnostics Create New Markets

Friday, February 26, 2021 - 12:00pm

DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Molecular Diagnostics for Cancer - Markets, Strategies and Trends.

Key Points: 
  • DUBLIN, Feb. 26, 2021 /PRNewswire/ -- The "Molecular Diagnostics for Cancer - Markets, Strategies and Trends.
  • Forecasts by Cancer Type, Including Companion Dx and by Country with Executive and Consultant Guides and COVID-19 Pandemic Recession Forecast Revisions.
  • Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth.
  • the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry.